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ABSTRACT
Objective Pneumonia accounts for more deaths than
any other infectious disease worldwide. The intestinal
microbiota supports local mucosal immunity and is
increasingly recognised as an important modulator of the
systemic immune system. The precise role of the gut
microbiota in bacterial pneumonia, however, is
unknown. Here, we investigate the function of the gut
microbiota in the host defence against Streptococcus
pneumoniae infections.
Design We depleted the gut microbiota in C57BL/6
mice and subsequently infected them intranasally with S.
pneumoniae. We then performed survival and faecal
microbiota transplantation (FMT) experiments and
measured parameters of inﬂammation and alveolar
macrophage whole-genome responses.
Results We found that the gut microbiota protects the
host during pneumococcal pneumonia, as reﬂected by
increased bacterial dissemination, inﬂammation, organ
damage and mortality in microbiota-depleted mice
compared with controls. FMT in gut microbiota-depleted
mice led to a normalisation of pulmonary bacterial
counts and tumour necrosis factor-α and interleukin-10
levels 6 h after pneumococcal infection. Whole-genome
mapping of alveolar macrophages showed upregulation
of metabolic pathways in the absence of a healthy gut
microbiota. This upregulation correlated with an altered
cellular responsiveness, reﬂected by a reduced
responsiveness to lipopolysaccharide and lipoteichoic
acid. Compared with controls, alveolar macrophages
derived from gut microbiota-depleted mice showed a
diminished capacity to phagocytose S. pneumoniae.
Conclusions This study identiﬁes the intestinal
microbiota as a protective mediator during
pneumococcal pneumonia. The gut microbiota enhances
primary alveolar macrophage function. Novel therapeutic
strategies could exploit the gut–lung axis in bacterial
infections.
INTRODUCTION
Pneumonia accounts for more deaths than any
other infectious disease worldwide.1 2 It is esti-
mated that every year nearly 12 million children
alone are hospitalised for severe pneumonia.2
Streptococcus pneumoniae, a Gram-positive bac-
teria that colonises the upper respiratory tract, is
the most frequent cause of community-acquired
pneumonia and a signiﬁcant cause of morbidity
and mortality worldwide.3 4 Growing levels of bac-
terial resistance have complicated the treatment of
pneumococcal infections. Thus, there is an urgent
need to expand our knowledge of the pathogenesis
of severe pneumonia caused by this common
pathogen.
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Signiﬁcance of this study
What is already known on this subject?
▸ The gut microbiota can enhance local defences
against enteral pathogens and is also believed
to inﬂuence systemic immunity.
▸ Gut microbiota metabolism of dietary ﬁbres
inﬂuences the severity of allergic inﬂammation
in mice.
▸ The role of the gut microbiota in the host
response to bacterial pneumonia is ill-deﬁned.
What are the new ﬁndings?
▸ The present study describes the role of the
intestinal microbiota in the host defence
against bacterial pneumonia.
▸ Mice with a depleted gut microbiota have
increased bacterial dissemination,
inﬂammation, organ failure and an accelerated
mortality when compared with controls
following infection with Streptococcus
pneumoniae, indicating that the intestinal
microbiota acts as a protective factor in the
host defence against pneumococcal
pneumonia.
▸ Faecal microbiota transplantation to gut
microbiota-depleted mice led to a
normalisation of pulmonary bacterial counts
and tumour necrosis factor-α and
interleukin-10 levels 6 h after pneumococcal
infection.
▸ The gut microbiota has a marked inﬂuence on
metabolic pathways within alveolar
macrophages, which correlates with an altered
cellular responsiveness. Macrophages in
microbiota-depleted mice have a diminished
capacity to phagocytose S. pneumoniae and
demonstrate a reduced cellular responsiveness
towards lipoteichoic acid and
lipopolysaccharide.
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For many years, it was hypothesised that in critically ill
patients the intestine plays a detrimental role by promoting sys-
temic inﬂammation and infection.5 More recently, however, the
intestinal microbiota—consisting of more bacteria than the total
number of cells in the human body—has emerged as positive
player in the host defence system, supporting mucosal immunity
and potentially modulating systemic immunity.6–13 The intes-
tinal microbiota may be of profound clinical relevance, particu-
larly for intensive care medicine where the majority of patients
are treated with antibiotics, which have pervasive and long-term
effects on their intestinal microbiota.9 14 What role does gut
microbiota play in bacterial pneumonia, however, remains
elusive.
We hypothesised that the gut microbiota bolsters the host
defence against S. pneumoniae. Therefore, we depleted the gut
microbiota in mice and studied subsequent infection with S.
pneumoniae. We provide evidence that the intestinal microbiota
acts as a protective factor in the host defence against pneumo-
coccal pneumonia and show that the gut microbiota enhances
primary alveolar macrophage function. Our studies provide a
basis for novel therapeutic strategies that exploit the gut–lung
axis in bacterial infection.
RESULTS
Protective role of the gut microbiota during pneumococcal
pneumonia
To ﬁrst gain insight into the role the intestinal microbiota plays
during bacterial pneumonia, we ﬁrst treated wild-type mice with
broad-spectrum antibiotics (ampicillin, neomycin, metronidazole
and vancomycin) in their drinking water in order to deplete the
gut microbiota.7 We then intranasally challenged them with
S. pneumoniae (106 colony forming units (CFU); ﬁgure 1A).
Microbiota-depleted mice had an accelerated mortality rate fol-
lowing S. pneumoniae infection (ﬁgure 1B). Supporting this
ﬁnding, gut microbiota-depleted mice had increased bacterial
loads in their lungs 6 h after S. pneumoniae challenge when
compared with age-matched controls and gut microbiota
mice had more bacteria in their blood 48 h post-infection
(ﬁgure 1C, D). Because the ability to combat invading patho-
gens strongly depends on the efﬁcacy of the local inﬂammatory
response,15 we measured the abundance of pulmonary cytokines
and chemokines. Interleukin (IL)-1β, IL-6 and CXCL1 were
increased, whereas tumour necrosis factor (TNF)-α and IL-10
levels were decreased 6 h after intranasal S. pneumoniae
infection in the gut microbiota-depleted mice compared with
controls (table 1). Lung cytokine levels at later time points were
similar between groups (table 1).
Faecal microbiota transplantation to gut
microbiota-depleted mice restores pulmonary bacterial
clearance and TNF-α and IL-10 levels early after
pneumococcal infection
We next aimed to verify that our mortality, bacterial load and
cytokine ﬁndings were gut microbiota dependent. Therefore, we
studied the effects orally administering intestinal microbiota
from healthy mice to microbiota-depleted mice had on the reci-
pients’ response to S. pneumoniae infection. We ﬁrst established
that broad-spectrum antibiotic treatment did not inﬂuence gut
architecture or epithelial integrity (ﬁgure 1E). In addition, we
tested whether the lung barrier might be impaired in the
absence of a healthy microbiota by measuring bronchoalveolar
lavage ﬂuid (BALF) protein contents. No differences in BALF
protein contents were observed after antibiotic treatment (see
online supplementary ﬁgure S1). In correspondence with our
hypothesis, faecal microbiota transplantation (FMT) to
gut microbiota-depleted mice could restore the diminished bac-
terial clearance in the lung early after pneumococcal infection
(ﬁgure 1F). In addition, FMT led to a normalisation of TNF-α
and IL-10 levels in the lung 6 h after infection, comparable with
non-depleted control mice (table 2). However, faecal transplant-
ation did not signiﬁcantly affect the number of S. pneumoniae
present in the blood when compared with antibiotic-treated
mice or controls (data not shown) nor did it signiﬁcantly affect
IL-1, IL-6 or CXCL1 levels (table 2). To assess the magnitude
by which our antibiotics7 reduced bacterial numbers in the gut,
we evaluated the murine faeces using a phylogenetic microarray
analysis of over 16 000 intestinal small subunit ribosomal RNA
sequences and determined the diversity index.16 17 Antibiotic
treatment led to a signiﬁcant drop in the microbial diversity,
which was signiﬁcantly reversed by transplantation of normal
faeces (ﬁgure 1G–I). Unsupervised clustering and principal com-
ponent analysis of the samples indicates a clear partitioning
between controls, antibiotic-treated and faecal transplantation
groups, which can explain 83.4% of the total data variance
(ﬁgure 1G–I). Taken together, these data establish that gut
microbiota depletion leads to a detrimental host response to
pneumococcal pneumonia as reﬂected by increased bacterial
counts and reduced survival.
The gut microbiota protects against organ damage during
S. pneumoniae-induced sepsis
To determine whether the protective role of the gut microbiota
on the pulmonary antibacterial host defence extended to organ
damage, we semiquantitatively scored lung histology slides from
gut microbiota-depleted mice and controls at various time
points after S. pneumoniae challenge. All infected mice showed
histological evidence of severe pneumonia. Consistent with the
observed increased bacterial outgrowth, at 6 h post-infection
microbiota-depleted mice displayed earlier and signiﬁcantly
more inﬂammation in their lungs compared with controls,
demonstrated by enhanced interstitial inﬂammation, endothelia-
litis and oedema (ﬁgure 2A). This difference in pulmonary
organ damage was even more pronounced at 24 and 48 h
(ﬁgure 2B, C). Since recruitment of leucocytes to infectious sites
is an essential step in the host’s defence against pneumonia,3 we
next analysed Gr-1 stainings in lung tissue and found increased
neutrophil inﬂux in the gut microbiota-depleted mice (see
online supplementary ﬁgure S2). Depletion of the intestinal
microbiota during S. pneumoniae infection also resulted in an
enhanced detrimental systemic inﬂammatory response. Although
no differences in systemic cytokine levels (TNF-α, IL-6, IL-10,
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ Our data identify a gut–lung axis during infection and
establish a mechanism for pulmonary immunomodulation via
the intestinal microbiota. These results highlight the
possibility that broad-spectrum antibiotics and disruption of
the intestinal microbiota may diminish innate immune
defences to infection. Novel therapies to treat severe
pneumonia could focus on the gut–lung axis in bacterial
infection.
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Figure 1 Protective role of the gut microbiota during pneumococcal pneumonia. (A) Experimental design. Group of eight wild-type mice were
treated for 3 weeks with broad-spectrum antibiotics (ampicillin, neomycin, metronidazole and vancomycin) in their drinking water compared with
untreated controls. Two days post treatment mice received an intranasal challenge with 1×106 colony forming units (CFU) of Streptococcus
pneumoniae. Subsequently, mouse survival, bacterial outgrowth and cytokine release were determined at various time points post S. pneumoniae
infection. (B) Survival of mice treated with broad-spectrum antibiotics compared with untreated controls before intranasal challenge with 1×106 CFU
of S. pneumoniae. (C) Pulmonary bacterial counts 6 h after S. pneumoniae infection in untreated (black) and microbiota-depleted (white) mice.
(D) Blood bacterial counts 48 h after S. pneumoniae infection in untreated (black) and microbiota-depleted (white) mice. (E) Representative small
intestine sections of untreated (upper row) and microbiota-depleted (lower row) mice demonstrate intact epithelial integrity with H&E, Ki67
(proliferation restricted in the crypt), MUC2 (goblet cell differentiation) and ChromograninA (neuroendocrine cell differentiation) stainings in both
groups. (F) Effect of faecal microbiota transplantation to gut microbiota-depleted mice on lung bacterial counts 6 h after intranasal S. pneumoniae
infection. (G) The magnitude by which the antibiotic protocol depleted the gut microbiota was assessed using a phylogenetic microarray in which
microbiota composition samples were clustered based on principal component analysis (PCA), (H) Pearson Clustering and (I) the Shannon Diversity
Index. Group size is 8–12 per group; results are shown as means±SEM; n.s. denotes not signiﬁcant; *p<0.05.
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IL-12, IFN-γ and MCP-1) could be observed between groups
(see online supplementary ﬁgure S3), 48 h after infection gut
microbiota-depleted mice had enhanced tissue inﬂammation and
damage (liver ﬁgure 2D,E) and hepatic injury as reﬂected by ele-
vated plasma concentration of aspartate aminotransferase, alanine
aminotransferase and lactate dehydrogenase (ﬁgure 2F–I). Kidney
function, as measured by urea and creatinine, was not affected
(ﬁgure 2F and see online supplementary ﬁgure S4). These results
suggest that the gut microbiota protects against organ injury
during S. pneumoniae-induced sepsis.
Effect of intestinal microbiota depletion on the alveolar
macrophage transcriptome
Because it has been described that the intestinal microbiota can
constitutively prime bone marrow-derived neutrophils and
augment their capacity to kill microorganisms,7 we further
hypothesised that a similar axis exists between the gut microbiota
and alveolar macrophages, which are the major orchestrators of
the pulmonary immune response following pathogen invasion.4 15
To test this hypothesis and to deﬁne the mechanism by which the
gut microbiota exerts its protective effects during pneumonia, we
ﬁrst analysed genome-wide transcriptional responses in alveolar
macrophages. Alveolar macrophages were isolated from unin-
fected but gut microbiota-depleted mice and controls. Depletion
of the intestinal microbiota had a substantial effect on the alveolar
macrophage transcriptome: considering multiple comparison-cor-
rected (Benjamini–Hochberg) p values, 80 unique genes were
found to discriminate between alveolar macrophages derived from
gut microbiota-depleted mice and controls (ﬁgure 3A). Ingenuity
pathway analysis revealed enrichment of the superpathway of chol-
esterol biosynthesis and zymosterol biosynthesis canonical signal-
ling pathways (ﬁgure 3B). Genes within these pathways include
Idi1, encoding isopentenyl-diphosphate-delta-isomerise-1 and
Acat2, encoding acetyl-Coenzyme-A-acetyltransferase-2. These
transcriptome differences suggest marked alterations in the meta-
bolic status of lung alveolar macrophages after gut microbiota
depletion.
The gut microbiota enhances primary alveolar macrophage
function
Cholesterol biosynthesis plays an important role in the antibac-
terial effector functions of alveolar macrophages.18 19 Blockade
of cholesterol synthesis signiﬁcantly inhibits the function of
cholesterol-rich membrane rafts and as a result the phagocytosis
of Pseudomonas aeruginosa by alveolar macrophages.19 Alveolar
macrophage phagocytosis is one of the prime host defence
mechanisms during pneumococcal infection and pneumonia.4 15
Given the observed effect of gut microbiota depletion on the
cholesterol biosynthesis pathway, we next studied whether gut
microbiota depletion altered the phagocytosis of S. pneumoniae
by alveolar macrophages. To do this, we harvested primary
alveolar macrophages from uninfected gut microbiota-depleted
and control mice and compared their ability to internalise
CFSE-labelled S. pneumoniae. We found that alveolar macro-
phages derived from gut microbiota-depleted mice had a dimin-
ished capacity to phagocytose S. pneumoniae when compared
Table 1 Pulmonary cytokine concentrations in untreated and microbiota-depleted mice during pneumococcal pneumonia
Time after Streptococcus pneumoniae infection
6 h 24 h 48 h
TNF-α
Untreated 2038 (1306–2130) 1950 (1722–2449) 123.6 (109.5–174.9)
Microbiota depleted 1021 (707.3–1091)** 1074 (929.4–1277)** 152.3 (134.5–494.5)
IL-1
Untreated 96.6 (52.6–106.5) 62.4 (57.9–236.1) 48.7 (43.5–53.7)
Microbiota depleted 120.9 (89.7–128.2)* 109.3 (80.0–204.8) 64.5 (47.7–122.0)
IL-6
Untreated 71.4 (42.0–86.5) 80.4 (42.1–538.4) 105.2 (98.4–125.5)
Microbiota depleted 110.8 (90.2–152.9)* 100.7 (52.2–192.9) 117.1 (99.6–312.8)
IL-10
Untreated 41.3 (29.9–60.84) 75.7 (45.0–91.4) 48.4 (30.7–77.3)
Microbiota depleted 21.4 (10.5–27.4)* 45.2 (19.6–52.9) 51.43 (43.7–80.4)
CXCL1
Untreated 125.5 (68.5–147.4) 87.8 (60.4–839.1) 54.3 (44.5–226.8)
Microbiota depleted 247.3 (155.1–455.1)** 132.1 (59.1–448.1) 44.3 (23.9–134.8)
Data are expressed as median (IQR) of n=8 mice per group per time point (6 h, 24 h or 48 h post intranasal challenge with S. pneumoniae). Measurements are expressed in pg/mL.
**p<0.01 for Untreated versus Microbiota-depleted mice (Mann–Whitney U test).
*p<0.05 for Untreated versus Microbiota-depleted mice (Mann–Whitney U test).
CXCL1, (C-X-C motif) ligand 1; IL, interleukin; TNF-α, a tumour necrosis factor-α.
Table 2 Pulmonary cytokine concentrations in untreated and
microbiota-depleted mice with and without faecal microbiota
transplantation during pneumococcal pneumonia
Untreated Microbiota depleted Faeces transplant
TNF-α 878.5 (588.5–1185) 552.9 (476.8–764.2)* 858.9 (660.4–1564)
IL-1 122 (61.59–166.8) 232.5 (143.5–342.1)* 217 (129–307.1)*
IL-6 198.9 (95.72–240.2) 419.4 (279.2–555.6)** 326.8 (210.8–454.7)*
IL-10 227.7 (160–300.3) 123.7 (116.8–128.1)* 174.4 (153.7–189)
CXCL1 144.6 (84.43–223.7) 384.4 (260.3–533.9)*** 242.9 (185.4–271)*
Data are expressed as median (IQR) of n=8 mice per group per time point.
Measurements are expressed in pg/mL.
*p<0.05 for Untreated versus Microbiota depleted or for Untreated versus Faeces
transplant mice (Mann–Whitney U test).
**p<0.01 for Untreated versus Microbiota depleted or for Untreated versus Faeces
transplant mice (Mann–Whitney U test).
***p<0.001 for Untreated versus Microbiota depleted or for Untreated versus Faeces
transplant mice (Mann–Whitney U test).
CXCL1, (C-X-C motif) ligand 1; IL, interleukin; TNF-α, a tumour necrosis factor-α.
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with controls, which may explain the in vivo phenotype
observed in the gut microbiota-depleted mice (ﬁgure 4A). Gut
microbiota-dependent phagocytosis was compartment depend-
ent: whole-blood neutrophils (ﬁgure 4B), but not peritoneal
macrophages (ﬁgure 4C) derived from microbiota-depleted mice
showed an equal defect in their phagocytosis capacity compared
with controls. Responsiveness of alveolar macrophages derived
from gut microbiota-depleted mice towards lipoteichoic acid
(LTA; ﬁgure 4D, E) or lipopolysaccharide (LPS; ﬁgure 4F, G)
was also markedly diminished compared with controls in terms
Figure 2 The gut microbiota protects
against organ failure during
Streptococcus pneumoniae-induced
sepsis. (A–C) Representative lung
slides of untreated (left) and
microbiota-depleted (right) mice
infected with 1×106 colony forming
units (CFU) of S. pneumoniae via the
intranasal route and euthanised at
indicated time points (6, 24 and 48 h)
thereafter to assess pulmonary
inﬂammation and total lung
histopathology scores (see Materials
and methods). H&E staining; original
magniﬁcation, ×100. (D and E) Liver
and spleen histology shown 48 h after
infection. H&E staining; original
magniﬁcation, ×200 for liver, ×100 for
spleen. (F) Systemic blood urea
nitrogen (BUN), (G) aspartate
aminotransferase (AST), (H) alanine
aminotransferase (ALT) and (I) lactate
dehydrogenase (LDH) levels assessed
48 h after infection in untreated (black)
and gut microbiota-depleted (white)
mice. Group size is 8 per group; results
are shown as means±SEM; n.s.
denotes not signiﬁcant; *p<0.05 and
**p<0.01.
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of cytokine release. The observed effect of the gut microbiota
was compartment dependent; whole blood (ﬁgure 4H), but not
peritoneal macrophages derived from gut microbiota-depleted
mice showed a diminished responsiveness towards LTA or LPS
when compared with controls (ﬁgure 4I–L). Taken together,
these data conﬁrm that the gut microbiota enhances primary
alveolar macrophage function and that an unperturbed gut
microbiota enhances responsiveness to bacterial virulence
factors and increases phagocytosis capacity.
DISCUSSION
Each year, 3.5 million deaths are attributed to pneumonia,
although this number is probably an underestimation, since deaths
from sepsis and deaths attributed to other conditions (eg, cancer
and Alzheimer’s disease) for which pneumonia is the terminal
event are coded separately.1 20 Pneumonia is the most common
cause of sepsis and S. pneumoniae is the most frequently isolated
pathogen in pneumonia resulting in sepsis. Recent breakthroughs
in our understanding of the role of the gut microbiome in both
health and disease can therefore have considerable implications for
respiratory and critical care medicine.9 11–13 Here, we show that
the gut microbiota plays a protective role during S. pneumoniae
pneumonia as evidenced by the increased bacterial dissemination,
inﬂammation, organ failure and mortality in microbiota-depleted
mice compared with controls. FMT to gut microbiota-depleted
mice led to a normalisation of pulmonary bacterial counts and
TNF-α and IL-10 levels 6 h after pneumococcal infection. The gut
microbiota enhances primary alveolar macrophage function both
in terms of cellular responsiveness to LTA and LPS and the capacity
to phagocytose S. pneumoniae.
Our work underscores the concept that the large community
of intestinal microbes not only contributes to the local host
Figure 3 Effect of intestinal microbiota depletion on the alveolar macrophage transcriptome. (A) Unsupervised hierarchical clustering heatmap of
the signiﬁcant (multiple comparison adjusted p<0.05) differentially expressed genes between untreated control and gut microbiota-depleted lung
alveolar macrophages. Red denotes increased expression; blue denotes decreased expression. (B) Stacked bar plot depicting the signiﬁcantly
enriched canonical signalling pathways (ingenuity pathway analysis) and expression patterns. –log(B–H)p, negative log-transformed Benjamini–
Hochberg-adjusted Fisher test p value. Ratio, ratio of input genes to pathway genes. Red denotes increased expression in gut microbiota-depleted
alveolar macrophages; green denotes decreased expression in gut microbiota-depleted alveolar macrophages.
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defences against infections, but also modulates immune
responses at systemic sites.7 9 11–13 21 Clarke et al were among
the ﬁrst to demonstrate that systemic innate immune responses
can be enhanced by translocation of microbiota-derived pro-
ducts from the intestine. Bone marrow-derived neutrophils
obtained from gut microbiota-depleted mice are less capable of
killing S. pneumoniae and Staphylococcus aureus in vitro.7
Similarly, intestinal microbiota-primed alveolar macrophages
show increased reactive oxygen species-mediated killing of
Klebsiella pneumoniae.22 In this line, the microbiota has been
shown to regulate immune defences against respiratory tract
inﬂuenza A virus infection.23 24 Trompette et al11 established
the existence of a gut–lung axis in allergic airway disease by
showing that gut microbiota metabolism of dietary ﬁbres inﬂu-
ences the severity of allergic inﬂammation. Alveolar macro-
phages, which are resident pulmonary macrophages, are
thought to form the ﬁrst line of defence in the event of patho-
gen invasion towards the lung.4 15 We studied the effect of
intestinal microbiota depletion on the alveolar macrophage tran-
scriptome. This enabled us to demonstrate that the gut micro-
biota has a marked inﬂuence on metabolic pathways within
alveolar macrophages, which correlated with an altered cellular
responsiveness—as reﬂected by a diminished capacity to phago-
cytose S. pneumoniae and a reduced cellular responsiveness
towards LTA and LPS. It remains to be established, however,
which gut microbiota-derived factors are responsible for this
effect. In addition, we did not investigate whether faecal trans-
plantation could reverse the speciﬁc transcriptomic changes,
impaired immune effector functions of alveolar macrophages
and neutrophil inﬂux in our model. Lastly, it remains to be
determined whether the observed effects of gut microbiota
depletion during infection with S. pneumoniae also apply to
infections with other important causative agents of pneumonia.
Clearly, independent experiments are required to establish this.
Of potential clinical importance is our ﬁnding that the gut micro-
biota protects against organ failure during S. pneumoniae-induced
Figure 4 The gut microbiota enhances primary alveolar macrophage function. (A) Capacity of alveolar macrophages derived from gut
microbiota-depleted (white) mice and control (black) mice to phagocytose Streptococcus pneumoniae ex vivo for 30 min. (B) Capacity of
whole-blood neutrophils derived from gut microbiota-depleted (white) mice and control (black) mice to phagocytose S. pneumoniae ex vivo for
30 min. (C) Capacity of peritoneal macrophages derived from gut microbiota-depleted (white) mice and control (black) mice to phagocytose S.
pneumoniae ex vivo for 10 and 30 min. (D and E) Responsiveness of alveolar macrophages derived from gut microbiota-depleted (white) mice and
control (black) mice towards lipoteichoic acid (LTA) and (F and G) lipopolysaccharide (LPS) in terms of interleukin (IL)-6 and tumour necrosis factor
(TNF)-α production. (H) TNF-α production of whole blood derived from gut microbiota-depleted (white) mice and control (black) mice upon
stimulated with LPS. (I and J) LTA-stimulated peritoneal macrophages derived from gut microbiota-depleted mice (white) and controls (black). (K and
L) LPS-stimulated peritoneal macrophages derived from gut microbiota-depleted mice (white) and controls (black). Group size is 8 per group; results
are shown as means±SEM; n.s. denotes not signiﬁcant; *p<0.05, **p<0.01 and ***p<0.001.
Schuijt TJ, et al. Gut 2016;65:575–583. doi:10.1136/gutjnl-2015-309728 581
Gut microbiota
group.bmj.com on April 10, 2016 - Published by http://gut.bmj.com/Downloaded from 
sepsis. This is illustrated by enhanced liver and hepatic injury in
mice in which the gut microbiota was depleted before intranasal
infection with S. pneumoniae when compared with controls.
Interventions to modulate the microbiota composition in the intes-
tine by replacing the microbiota or by treating patients with
selected microbial products are promising new treatment strategies
for the critically ill.9 Avery recent report described the ﬁrst success-
ful use of FMT in the treatment of a critically ill patient with
therapy-resistant sepsis.25 The ﬁnding that Lactobacillus rhamnosus
administration is safe in critically ill patients and efﬁcacious for the
prevention of ventilator-associated pneumonia further underscores
the therapeutic potential of targeting the gut microbiota in
pneumonia-derived sepsis.26
Caution is needed when extrapolating data from mouse
experiments to human disease. Murine models like the one used
here make use of a homogenous group of experimental animals
with identical genotype, sex and (relatively young) age which
are exposed to a well-controlled bacterial challenge, whereas
patients form a heterogeneous group in which multiple factors
modify disease outcome, including the extent of pathogen
exposure, older age, comorbidities, comedications and genetic
composition. In addition, it should be noted that FMT in gut
microbiota-depleted mice did not reverse all endpoint para-
meters in our model of bacterial pneumonia. Despite these
caveats, the present study now describes a possible role of the
gut microbiota in modulating both local and systemic host
responses to a clinically relevant model of pneumonia. Our
work demonstrates that the intestinal microbiota plays a protect-
ive role in the host defence against S. pneumonia-induced pneu-
monia through priming of alveolar macrophages. These results
highlight the possibility that broad-spectrum antibiotics and dis-
ruption of the intestinal microbiota may diminish innate
immune defences to infection. Our data identify a gut–lung axis
during infection and establish a mechanism for pulmonary
immunomodulation by the intestinal microbiota.
MATERIALS AND METHODS
Mice
Speciﬁc pathogen-free C57Bl/6 mice were purchased from
Harlan Laboratories. The known variation in intestinal micro-
biota composition between inbred C57BL/6 mice derived from
one commercial vendor is known to be highly limited.27
Offspring and diet are major determinants of gut microbiota
composition.28 29 Experimental groups were age and sex
matched, and housed in the Animal Research Institute
Amsterdam (ARIA) facility of the Academic Medical Center
facility under standard care. All experiments were conducted
with mice between 10 and 12 weeks of age.
Experimental study design
Pneumonia was induced by intranasal inoculation with 1×106
CFU S. pneumoniae D39 as previously described.30–32 For sur-
vival experiments, mice were checked every 6 h until death
occurred. Sample harvesting, determination of bacterial growth
and analysis (including pathology and immunohistochemistry)
are described in the online supplementary ﬁle. In order to
deplete the gut microbiota, mice were treated with broad-
spectrum antibiotics (ampicillin 1 g/L, Sigma; neomycin sulfate
1 g/L, Sigma; metronidazole 1 g/L, Sanoﬁ-Aventis and vanco-
mycin 0.5 g/L, Sandoz) in drinking water for 3 weeks as
described.7 Two days after cessation of antibiotic drinking water,
mice were inoculated with S. pneumoniae. RNA preparation
from alveolar macrophages and microarray proﬁling are
described in the online supplementary ﬁle.
Faecal transplantation
Faecal pellets from untreated mice were resuspended in PBS (1
faecal pellet/1 mL of PBS). For each experiment, several faecal
pellets from different untreated mice were resuspended together
in PBS. A total of 200 μL of the resuspended pool faecal mater-
ial was given by oral gavage to gut microbiota-depleted mice
over 4 consecutive days after antibiotic treatment was stopped;
control mice were given water alone during this period.33
Microbiota analyses
Fresh stool pellets were obtained before mice were euthanised.
The samples were immediately frozen and stored at −80°C. DNA
isolation was performed using a modiﬁed repeated beating
method.34 35 16S rRNA gene ampliﬁcation, in vitro transcription
and labelling and hybridisation were carried out as described pre-
viously.17 Data analyses were performed using the microbiome
R-script package as described in the online supplementary ﬁle.
Ex vivo experiments
Murine alveolar macrophages and neutrophils were isolated,
washed and incubated as described.36 37 Details on the phago-
cytosis and cell stimulation experiments are provided in the
online supplementary ﬁle.
Ethics statement
The Institutional Animal Care and Use Committee of the
Academic Medical Center, University of Amsterdam, reviewed
and approved all experiments (identiﬁcation number:
DIX100121AE). The animal care and use protocol adhered to
European Directive of 22 September 2010 (Directive 2010/63/
EU) in addition to the Directive of 6 May 2009 (Directive
2009/41/EC).
Statistical analysis
Comparisons between groups were ﬁrst performed using
Kruskal–Wallis one-way analysis of variance (ANOVA) test; in
case of signiﬁcant differences, differences between groups were
tested using the Mann–Whitney U test (GraphPad Prism 5). We
used the Kaplan–Meier log-rank test to compare survival
between groups. Statistically signiﬁcant differences are indicated
as follows: *p<0.05; **p<0.01; ***p<0.001. Linear model
ANOVAwas employed to deﬁne alveolar macrophage transcripts
inﬂuenced by broad-spectrum antibiotic treatment. Unless other-
wise stated, a false discovery rate-corrected p value (q-value)
was used to deﬁne genome-wide signiﬁcance.
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